Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
€ 0.76
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable analyst view
Data is available to registered users only
Data is available to registered users only
About
Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Data is available to registered users only
Target Price
The average target price of SEQUA.BR is 2.9 and suggests 283% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in
Data is available to registered users only
